Injectables deal prospect drums up India's Claris
This article was originally published in Scrip
Executive Summary
Renewed speculation around a potential sell-off of Claris Lifesciences' injectables business saw the firm's shares make strong gains on Indian bourses on 21 May, a day ahead of its scheduled earnings announcement.
You may also be interested in...
Baxter Injects $625m In ‘Foundational Asset’ Claris
Baxter has snapped up India’s Claris Injectables, accelerating efforts to become a global leader in generic injectables. The deal also puts the spotlight back on the significant M&A appetite in the niche injectables segment and the scarcity premiums that such assets can command.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet